I-AstraZeneca ifumana unyuso lolawulo lwamachiza e-oncology

I-AstraZeneca ifumene ukongezwa okuphindwe kabini kwipotfoliyo yayo ye-oncology ngoLwesibini, emva kokuba abalawuli base-US naseYurophu bamkele ukungeniswa kolawulo lwamachiza ayo, inyathelo lokuqala lokuphumelela ukuvunywa kwala mayeza.

Umenzi weziyobisi wase-Anglo-Swedish, kunye ne-MedImmune, ingalo yayo yophando lwebhayoloji kunye nophuhliso lwehlabathi, yabhengeza ukuba i-US Food and Drug Administration (FDA) isamkele isicelo selayisensi ye-moxetumomab pasudotox, iyeza elitsha elinokubakho kunyango lwezigulana zabantu abadala abaneeseli ezinoboya. i-leukemia (HCL) abaye bafumana ubuncinane imigca emibini yonyango yangaphambili.

I-FDA inike ichiza "uphononongo oluphambili", olunikezelwa kumayeza athi, ukuba avunyiwe, abonelele ngophuculo olubalulekileyo kunyango, ukuxilongwa, okanye uthintelo lweemeko ezimandundu. Kulindeleke isigqibo kwikota yesithathu yalo nyaka.

Ngokwahlukileyo, i-Arhente yaMayeza yaseYurophu yamkele ukungeniswa okusemthethweni kwe-Lynparza, ichiza i-AstraZeneca ngoku esebenzisana nayo ngo-50:50 ubambiswano kunye noMerck, inkampani yamachiza yase-US, ukunyanga umhlaza wamabele osasazeka kwenye indawo emzimbeni kwizigulana ezinento ethile. ukuguqulwa kofuzo.

Ukuba livunyiwe, iyeza liya kuba yi-PARP inhibitor yokuqala kunyango lomhlaza wamabele eYurophu. I-PARP yiprotheyini efumaneka kwiiseli zomntu ezinceda ezo seli ukuba zizilungise ngokwazo xa zonakele. Ngokumisa le nkqubo yokulungisa kwiiseli zomhlaza, i-PARP inhibitors inceda iseli ukuba ife.

I-Lynparza ngoJanuwari yaba yi-PARP inhibitor yokuqala evunyiweyo naphi na kwihlabathi lomhlaza webele, xa iphumelele i-go-ahead evela kubalawuli base-US.

Kulingo lwamva nje, iLynparza yolule kakhulu ukusinda okungaqhubekiyo xa kuthelekiswa nechemotherapy kwaye yanciphisa umngcipheko wokuqhubekeka kwesifo okanye ukufa ngeepesenti ezingama-42.

Ngo-2017 isihlanu sentengiso yemveliso ye-Astra yayivela kwi-oncology kwaye inkampani ilindele ukuba lo mlinganiselo unyuke. Izabelo kwiqela zivale i-0.6 yeepesenti kwi-£ 49.26.

Kuphuhliso olwahlukileyo, iCompugen, inkampani yamayeza yakwa-Israeli, yathi ingene kwisivumelwano selayisensi esikhethekileyo neMedImmune esiza kwenza ukuba kuphuhliswe iimveliso ze-antibody ukunyanga umhlaza.

I-MedImmune inelungelo lokudala iimveliso ezininzi phantsi kwelayisenisi "kwaye iya kuba noxanduva kuphela kulo lonke uphando, uphuhliso kunye nemisebenzi yorhwebo phantsi kwesivumelwano", utshilo uCompugen.

Inkampani yakwa-Israeli iya kufumana i-10m yentlawulo yangaphambili kwaye ifanelekile ukufumana ukuya kuthi ga kwi-200 yezigidi zeedola kuphuhliso, ulawulo kunye neziganeko zentengiso kwimveliso yokuqala, kunye nentlawulo kwintengiso yemveliso yexesha elizayo.

U-Anat Cohen-Dayag, umphathi oyintloko weCompugen, uthe isivumelwano "sivumela ukuba senze imali kwinkqubela phambili yenzululwazi kwiinkqubo zethu, ngelixa siqhubeka nokuqhubela phambili iinkqubo zethu zokukhokela kwiimvavanyo zekliniki".